T cell receptor (TCR)-recognizing regulatory cells, induced after vaccination with self-reactive T cells or TC1K peptides, have been shown to prevent autoimmunity. We have asked whether this regulation is involved in the maintenance of peripheral tolerance to myelin basic protein (MBP) in an autoimmune disease model, experimental autoimmune encephalomyelitis (EAE). Antigen-induced EAE in (SJL X B10.PL)F1 mice is transient in that most animals recover permanently from the disease. Most of the initial encephalitogenic T cells recognize MBP Acl-9 and predominantly use the TCR V[38.2 gene segment. In mice recovering from MBP-induced EAE, regulatory CD4 + T cells (Treg) specific for a single immunodominant TCR peptide B5 (76-101) from framework region 3 of the V[38.2 chain, become primed. We have earlier shown that cloned B5-reactive Treg can specifically downregulate responses to Acl-9 and also protect mice from EAE. These CD4 Treg clones predominantly use the TCtL V[314 or VI33 gene segments. Here we have directly tested whether deletion/blocking of the Treg from the peripheral repertoire affects the spontaneous recovery from EAE. Treatment of F1 mice with appropriate V[3-specific monoclonal antibodies resulted in an increase in the severity and duration of the disease: even relapses were seen in one-third to one-half of the Treg-deleted mice. Interestingly, chronic disease in treated mice appears to be due to the presence of Acl-9-specific T cells. Thus, once self-tolerance to MBP is broken by immunization with the antigen in strong adjuvant, TCR peptide-specific CD4 Treg cells participate in reestablishing peripheral tolerance. Thus, a failure to generate Treg may be implicated in chronic autoimmune conditions.
F
or most of the history of immunology, it had been thought that the modus operandi of the immune system required discrimination between self and nonself, leading to a prevention of response to the former. The presence of self-reactive T ceils and the primacy of self-recognition is now considered essential for the normal functioning of the immune system. Indeed, since positive selection is based on recognition of self-peptides in a self-MHC context, to one extent or another, it is clear that responses to foreign antigens depend on cross-reactivity with self (1-3). The ease with which self-reactive T cells can be detected in normal individuals is one indication that negative selection is incomplete and that other mechanisms must operate subsequently to maintain peripheral tolerance to self.
Therefore, self-tolerance to at least some tissue-specific antigens is not entirely a passive process but rather an active dynamic state in which potentially pathogenic self-reactive T cells are prevented from causing disease by other regulatory T cells (4) . The differential secretion of lymphokines by T cell subsets offers an explanation for the ability of certain T cells to induce autoimmunity and others to regulate these autoreactive T cells (5) . Thl cytokines have been shown to be involved in cell-mediated autoimmune diseases. For example, IFN-~/, lymphotoxin, or TNF-o~ secretion correlate with the encephalitogenic capacity of T cell clones reactive to myelin basic protein (MBP) 1 (6) . Anti-TNF-cl antibodies have been shown to inhibit experimental autoimmune encephalitis (EAE) and collagen-induced arthritis while anti-TGF-[3 accelerates the disease (reviewed in 4, 5) . Both TGF-[3 and IL-10 can play an important role in regulating autoimmune inflammatory reactions.
Similarly, ifimmunoregulatory mechanisms malfunction, the resulting deficiency of regulatory T cells could lead to autoimmunity. For example, depletion of a particular subset of T cells results in thyroiditis in mice (7) ; athymic rats reconstituted with CD45RB high CD4 + T cells alone develop a severe autoimmune condition but when reconstituted with both CD45R~ high and regulatory CD45RB l°w 1Abbreviations used in this paper: EAE, experimental autoimmune encephalomyelitis; MBP, myelin basic protein; PPD, purified protein derivative of mycobacterium tuberculosis; PTx, pertussis toxin; Treg, regulatory CD4 + T cells.
T cells they were devoid of autoimmune inflammation (8) . These and other neonatal depletion and reconstitution experiments suggest that a determining factor in the expression ofautoimmunity is the equilibrium between autoreactive and regulatory T cells (9) .
EAE is a T cell-mediated autoimmune demyehnating disease of the central nervous system that can be induced after immunization with MBP or its peptide fragments. The TC1Ks of MBP-reactive T cells in several strains of mice and rats have been shown to be encoded by a limited set of V-region gene segments (10) (11) (12) (13) . After immunization with MBP, most CD4 + T cells in B10.PL or PL/J mice recognize the immunodominant NH2 terminal peptide Acl-9 and a majority of CD4 ÷ T cells use the TCR V]38.2 gene segment (10, 11) . The limited repertoire of TCR V genes engaged in response to MBPAcl-9 has allowed the use of mAbs to V[38 in vivo to successfully prevent or treat EAE (10, 11) .
Regulatory responses capable of protecting animals from autoimmunity can be raised to the V region of the TCR after vaccinafon with disease-causing, MBP-reacfve CD4 + T cells or more recently, after immunization with TCR peptides from the CDR II (amino acids 39-59) or the framework III (amino acids 76-101) region of the TCIK-]3 or the CDR III region of the TCP,-ot chain of encephalitogenic T cells (14) (15) (16) (17) . We have clearly established in the murine model that protection from EAE by TCt< peptides can be mediated by regulatory T cells that are physiologically induced after MBP or Acl-9 immunization (18). We have characterized TCR peptide-reactive T cells at the clonal level and their physiological role during the course of EAE. We have studied the dynamics of the spontaneous physiological induction of anti-TCR-peptide responses during EAE in B10.PL mice. It was shown that T cells directed against the dominant TCR-peptide of V138.2, B5 (76-101), generally were primed during recovery from MBP-induced EAE without the necessity for external challenge by TCR peptides. We have isolated V]314-expressing T cell lines, clones, and T cell hybridomas specific for B5, a peptide encompassing framework region 3 of the V~8.2 chain. These T ceils were CD4 +, CD8-, and MHC class II restricted. In adoptive transfer experiments, B5-reactive T cell clones, but not B4-specific T ceils, specifically inhibit proliferative responses to Acl-9 and protect mice from MBP-induced EAE.
Here we have asked whether physiologically activated TCP,-peptide B5-specific T cells are directly involved in mediating spontaneous recovery in (SJL × B10.PL)F1 mice. F1 mice were chosen for their consistent acute disease course (<10% of animals develop chronic symptoms) and high disease-incidence to MBP Acl-9-induced EAE. We show that after treating animals with mAbs against specific V]~-chains, predominantly used by regulatory CD4 + T cells (Treg) cells, there is delayed recovery and the mice contract chronic EAE. Upon reconstitution with cloned B5-specific T cells these V]3-depleted mice showed an accelerated recovery. Thus, TCR-peptide specific CD4 T cells that are spontaneously primed in F1 mice are involved in mediating spontaneous recovery from EAE. These findings describe the protective role of Treg cells in restoring peripheral tolerance and preventing outbreaks of EAE. We conclude that chronic and relapsing disease could be due to defective regulation.
Materials and Methods
Mice. SJL and B10.PL mice were purchased from The Jackson Laboratory, Bar Harbor, ME. (SJL × B10.PL)F1 mice were bred under specific pathogen-free conditions in our own colony. Female mice were used at 8-14 wk of age.
Antibodies. The following mAbs were used: anti-CD4-PE (GK1.5 from Becton Dickinson and Co., Mountain View, CA), anti-Vf~14 (14-2, rat IgiVl, 19), anti-V[35 (20) , and anti-V 21) . Anti-V]314 (14-2) antibodies acquired from PharMingen contained 0. i % (wt/vol) sodium azide. Two control experiments were done to rule out any effect ofazide on EAE: first, a desalting column was used to purify this IgM molecule; second, an equal amount of azide in saline (50-100 lal of 0.1% solution) was injected in control animals with no effect on EAE. The hybridomas producing anti-V]38.2 and anti-V]314 antibodies were generously provided by Drs. Michael Bevan (University of Washington, Seattle), and David Raulet (University of California, Berkeley), respectively. Since only a single anti-Vf314 mAb, 14-2, is available, attempts were made to differentiate simple receptor blocking vs depletion after antibody injection by in vitro culture of peripheral T cells with recombinant IL-2. 3 d after antibody injections, at a time when apparent depletion was detected (see Table 2 ), nucleated splenic cells were collected from mice given a single injection of the mAb and divided into two fractions. One fraction was immediately stained, whereas the other was cultured for 72-96 h with rlL-2 and then stained with anti-TCR monoclonals. The proportion of cells in each fraction that stained positively for V[314 was compared and found to be similar (0.5 vs 0.7), suggesting depletion of T cells.
TCR Peptides. TCR peptides used were same as reported previously (17, 18) and were synthesized by S. Horvath (Caltech, Pasadena, CA) using a solid-phase technique on a peptide synthesizer (model 430A; Applied Biosystems, Inc., Foster City, CA) and were purified on a reversed-phase column by HPLC (22) . 
Splenic Proliferation

Induction of EAE.
For induction of EAE, mice were immunized subcutaneously with 100 I, tg Acl-9 emulsified in CFA and 0.15 ~g pertussis toxin (PTx) (List Biological Laboratories, Inc., Campbell, CA) was injected in 200 I~1 saline intravenously 48 h later. Mice were observed daily for signs of EAE until >60-90 d after MBP Acl-9 immunization. Mice for some of the initial Treg-deletion experiments were monitored in a double-blind manner by two independent observers. The average disease score for each group was calculated by averaging the maximum severity of all of the affected animals in the group. Disease severity was scored on a five-point scale (18): 1, flaccid tail; 2, hind limb weakness; 3, hind limb paralysis; 4, whole body paralysis; 5, death. Tolerance Induction. Tolerance to TCR peptides was induced by two intraperitoneal injections at different doses, 14 or 50 nmol ofpeptides in IFA (50 Ixl), the first within 24 h after birth and the second 72 h after birth. 7-8 wk later, tolerized animals were immunized either with TCR peptides/CFA for proliferative T cell responses or with Acl-9/CFA/PTx for the induction of EAE. In one experiment, tolerized mice (8 wk old) were subsequently vaccinated with TCR peptides to study protection from EAE. Antigen-specific tolerance to MBP peptides was induced by intravenous injection of 400 Ixg peptide in 0.2 ml PBS, as described previously (23) .
Results
Spontaneous Priming of TCR Peptide B5-reactive T Cells in (SJL × BIO.PL)F1 Mice after Antigen Injection. To test whether
TCR-peptide B5-specific T cells become naturally primed during recovery from antigen-induced EAE in the (SJL × B10.PL)F1 mouse as well as in the B10.PL strain (18) , the specific proliferative response to B5 was followed in splenic T cells from mice challenged 25-35 d earlier with MBP/ CFA and PTx. A proliferative T cell response to another TCI< peptide B2, as control, was also followed in parallel. Clearly, a significant proliferative response to TCR peptide B5 was revealed in the peripheral T ceils from mice recovering from EAE ( Fig. 1 ). In contrast, there was no proliferative recall response to another proliferation-inducing or immunogenic TCR. peptide, B2. Also, no proliferation was detected in response to B5 in unimmunized mice or in MBP/CFA/PTx-immunized mice before the onset of EAE (data not shown). Thus, during the course of recovery from antigen-induced EAE, T cells reactive to the immunodominant framework region 3 TClq, peptide of the V[38.2 chain are generated in (SJL × B10.PL)F1 mice, consistent with our earlier observations in the B10.PL strain (18) .
Selection of V~14 +, CD4 + T Cells In Vivo. Our previous
analysis of 29 B5-specific B10.PL-derived T cell clones and hybridomas, showed an oligoclonal TCR VI3 gene usage: a distinct majority (26/29) ofT cells used V[314; three used VI33 gene segments (18) . To investigate the in vivo significance of this observation (without introducing a bias as a result of in vitro long-term growth and selection), peripheral T cells from mice recovering from antigen-induced EAE were sorted into VI314 + CD4 + and V[314-CD4 + T cell populations. Sorted populations were incubated in the presence of irradiated spleen cells from naive F1 mice with optimum concentrations of different peptides and the proliferative response was determined (Fig. 2) . A major proliferative response to B5, but not B2 was found in the V[314 + CD4 + T cell population. The diminutive response to B5 in the V~14-fraction could be due to the presence ofV~3 + T cells in this population. Because of a very low yield of VI33 + CD4 + T cells, we could not do a similar analysis. for the functional consequences of the response to t35 in recovery from EAE, attempts were made to induce tolerance in the CD4 Treg population. Groups of mice were neonatally tolerized with TCR peptides, B4, B5, or PBS (Table 1 ). 7-8 wk later, two mice from each group were challenged with the same peptides in CFA to test for proliferative responses. The remaining mice in each group were challenged with Acl-9/CFA/PTx to induce EAE. T cell proliferation in the draining LN populations in response to TCR peptides or purified protein derivative of mycobacterium tuberculosis (PPD) are shown in Table 1 . Mice neonatally tolerized to B4 and subsequently challenged with B4 did not proliferate. In contrast, B5-tolerized mice still showed a robust proliferative response to a subsequent challenge with B5. Responses to PPD were similar in all groups. In a separate experiment mice tolerized at a higher antigen level, with 50 nmol orB5, still showed a proliferative reponse to B5 (data not shown). The results showing that the incidence and severity of EAE in each group was very similar (Table 1) indicate that B5-specific T cells are not easily tolerized. Likewise, there was no functional tolerance induced and "B5-tolerized" mice could be significantly protected from EAE by subsequent vaccination with B5 as adults. This inability to induce neonatal tolerance to B5 along with the oligoclonality of the TCR V-gene usage led us to use the antibody-depletion approach to test directly the role ofB5-reactive T cells in recovery from EAE.
Injection of V~-Chain-specific mAbs Leads to a Significant Temporary Depletion of Corresponding V~-expressing T Cells.
Anti-TCR V[~ region-specific antibodies were used to deplete specific T cells in vivo. We initially used various amounts (25- Table 2) . A small population ofT cells representing ~15% of the original level of CD4 V[314-expressing T cells persisted after antibody injections and was not deleted even after injection with 250 txg of antibody. Since mAb 14-2 is IgM and is a rat-mouse hybrid, depletion may be inefficient owing to induction of an anti-rat immune response. Peripheral T cells from some mice were examined for the presence ofV1314 CD4 T cells at 2, 3, and 6 wk after antibody injection. Although at 2 wk a similar staining pattern to that after 3 d was seen, by 3 wk, normal levels of V[314 T cells had almost returned. Thus, depletion of V1314-expressing T cells after a single injection with the mAb is incomplete and appears to be relatively short term.
Anti-V~14 and Anti-V~3-treated Mice Develop Severe Chronic EAE.
We had shown earlier that cloned B5-specific CD4 V[314 T cells, when adoptively transferred into B10.PL mice, were able to down-regulate encephalitogenic MBP-reactive T cells and prevent MBP-induced EAE (18) . Alternatively, mice could be vaccinated with peptide B5 and could also be significantly protected from MBPinduced EAE (17) . To directly assess the physiological role ofV[314 + and/or V[33 + CD4 + Treg in spontaneous recovery from EAE, we have asked whether depletion/blocking of these cells affects the duration of disease in F1 mice.
DAYS AFTER IMMUNIZATION
To obtain a reproducible disease course from experiment to experiment, (SJL × B10.PL)F1 mice were immunized subcutaneously with 100 ~g of Acl-9 emulsified with CFA (no additional M. tuberculosis was added), followed by a single intravenous injection of 150 ng of PTx in saline, 48 h later. Disease incidence in this protocol was 90-100% and most of the animals (90-95%) showed an acute episode of EAE with spontaneous recovery. For antibody treatment, mice were divided into several groups: mice in one group were left untreated, whereas others were injected with various mAbs on the same day or 24 h after Acl-9/CFA injection. Results from one experiment are shown in Fig. 3 , and the data from three different experiments are summarized in Table 3 . Mice treated with anti-V[314 and anti-V~33 mAb had severe and chronic EAE, with most mice (9/9) recovering very slowly. In fact, some of the mice (30-45%) in the anti-V[314-treated group showed relapses and most recovered much later (days 48-70) than mice in the control groups (around day [25] [26] [27] [28] [29] [30] . Mice treated with anti-V[33 only showed no obvious changes in their recovery pattern and were similar to the control Ig-treated group. Mice were also treated with an irrelevant anti-TCR (V[35.1) antibody, as a control group, with no significant effect on EAE (Table 3) . It is clear that after a single anti-V[3 antibody injection, mice did recover eventually (in dig ferent experiments from days 48-70). In one experiment in which we injected mice on days 1, 14, 28, and 42 with both anti-Vf314 and anti-V[33 antibodies, recovery was further delayed in that 4/5 mice showed partial paralysis beyond day 70 (data not shown). Interestingly, mice in the combined anti-V[314-and anti-V[33-treated group did not stay severely sick (e.g., with a score of 4) but remained partially paralyzed in the tail and hind limbs (score 1 and 2). terminant, was injected in CFA with PTx, it was capable of causing EAE in B10.PL mice as well as in F1 mice (25, and Kumar, V., unpublished observation). It is not yet clear whether in vivo-primed T cells specific for these later determinants are encephalitogenic and/or participate in chronic EAE in this system. We wanted to test whether chronic disease or even relapses in some cases (30-45%) in the anti-V~-treated mice were due to the presence of T cells with specificities for determinants other than Acl-9, namely subdominant determinants, such as MBP81-100/A ~ or MBP121-140/A u. T cells specific for these determinants do not predominantly use V[38.2 or V[313 gene segments, which are prevalent among Acl-9~specific T cells. Therefore, anti-V[314/anti-V[33-treated mice were depleted of Acl-9~pecific T cells during the course of chronic EAE and their disease and recovery were followed. As shown in Table 4 , mice in the control group, with Acl-9-specific T cells intact, showed chronic EAE in that 7/7 mice still had clinical signs of the disease by day 35. In contrast, mice devoid of Acl-9-reactive T cells (anti-V[38.2-and anti-V~13-treated) showed accelerated recovery, despite the loss of Treg, and despite the presence of T cells directed to the subdominant determinant of MBP. Only 1 Out of 9 mice in this group showed clinical EAE by day 35.
Since non-Acl-9-reactive T cells, including T cells specific for other myelin antigens, could use V~8 + or V[33 + TCR, we induced antigen-specific tolerance and studied its effect on the chronicity of EAE in Treg-depleted mice.
Adoptive Transfer of the B5-specific, V~ 14-expressing Regulatory T Cell Clone B5.2 Accelerates Recovery in Anti-VAgtreated F1 Mice. We next wanted to test whether adoptively transferred B5-specific Treg cells could reestablish a regulatory balance and normalize the disease course in Tregdepleted mice. First, groups of mice (SJL × B10.PL)F1 were treated with anti-V~14 antibody, intraperitoneally, as in Fig. 3 . Mice in one of the anti-V[314-treated groups were injected (i.p.) with 106 cloned B5.2 T cells at the time (day 12) of onset of EAE. Mice in the other two groups were injected with either saline or with a B4-specific T cell clone, B4.1 (106). As shown in Fig. 4 , mice injected with the B5.2 clone recovered much earlier (4/5 mice recovered by day 36) than mice in the control anti-V[314 treated group (0/5 by day 36). Mice in the B4.1-injected group failed to recover in an accelerated fashion. It should be pointed out that at ~2 wk after injection, the anti-VI314 apparently had reduced to an ineffective level, so that the transferred B5.2 cells manage to perform their regulatory functions.
Chronic Disease and Relapses in Anti-V~8-treated Mice Are Due to the Presence of Dominant Peptide Acl-9-specific T Cells.
We have shown earlier that T cells specific for other subdominant determinants appear late in F1 mice after immunization with Acl-9 (24). Recently, we have shown that when peptide MBP121-140, containing a subdominant de- to deplete Acl-9-specific T cells. Mice were scored daily for symptoms of EAE until days 60 and 55, respectively. *P values between the control and Acl-9-<iepleted group was P <0.001, and was calculated using the chi-square test with Yates collection.
During the course of EAE (on day 14), mice were injected intravenously with 400 ~g of Acl-9 or MBP 41-58 peptide in saline (Table 4) . Mice tolerized with Acl-9 recovered relatively quickly (days [23] [24] [25] , whereas five out of five mice in the control group tolerized with MBP 41-58 contracted chronic disease and had tail paralysis beyond day 35. Thus, chronic EAE in Treg-depleted mice still seems to be driven by the presence ofAcl-9--specific T cells.
Discussion
We have attempted to determine the importance of the activation of VI314 and VI33 regulatory CD4 T cells in the development and course of EAE in the (SJL × B10.PL)F1 mice. In this strain, TCR-peptide~specific T cells specific for the immunodominant TCR 13-chain peptide B5 are physiologically induced via antigenic stimulation, without any exogenous challenge with the TCR peptide. Importantly, here we have shown that the deletion/blocking of CD4 V{B14+/V{B3 + Treg cells from the peripheral T cell repertoire leads to an increase in severity of EAE and poor recovery from disease in F1 mice.
TCR Peptide B5-specific T Cells Predominantly Expressing the V~14 Gene Segment Are Naturally Revealed in (SJL X BIO.PL)F1 Mice Recovering from Antigen-induced EAE.
Demonstration of the induction of TCR peptide B5-reactive CD4 T cells during the course of antigen-induced EAE suggests that a determinant within the B5 peptide (amino acids 76-101) from the V[38.2 chain of the T cell receptor is physiologically processed and presented in a class II (I-A u) context. There are two other peptides (B2 and B4) from the same V[3 chain that are capable of inducing T cell proliferative responses when the peptide form is used for immunization (17) . These latter peptides seemingly are not naturally processed and presented, at least in the presence orB5, because spontaneous T cell reactivity to them is not detected during the course of EAE.
Determinant(s) within the B5 peptide appear to be dominant: first, LN cells from mice challenged with recombinant single-chain TCR molecules containing the entire V[38.2 chain, respond to B5 in in vitro proliferative recall assays and not to other TCP,. peptides (Kumar, V. et al., manuscript submitted for publication); second, spleen cells from naive animals are capable of stimulating B5-reactive T cell clones in vitro in the absence of exogenous peptide (18) . Thus, APCs appear to constitutively process and potentially present B5 in vivo. In view of the prevalence of the TC1L V[38 family in peripheral T cells (15-30%), it is not surprising that TCR V[38 peptides are generated which are capable of binding to MHC molecules in vivo. Among these, B5 seems to possess the appropriate combination of availability and affinity of binding to A u to render it dominant. Another possible interpretation is that some other molecule(s) on the surface of splenic APC could be crossreactive (26) and mimic the B5 TC1K determinant. We are currently examining these issues.
Typically, dominant determinants on self-antigens induce thymic tolerance (23) . Thus, why is the T cell repertoire directed against the dominant TCP, peptide B5 still intact? Are these TCR.-peptide-MHC complexes not present in the thymus or do they fail to mediate negative selection? It is hkely that if determinants in the B5 region were able to be processed and presented by the thymic APCs, T cells expressing only high affinity TCR would be deleted sparing the low affinity TCR-bearing T cells to be positively selected. Our data demonstrate an inability to induce neonatal tolerance to B5 and is consistent with the idea that most B5-specific T cells are not deleted, but rather may be primed, as has recently been reported (27) . These results are similar to a recent report in the rat model where neonatal tolerance to the CDI<2 peptide does not lead to a change in the course of EAE (28) . However, rats tolerized as adults to this peptide contract severe disease (28) . V1814 and~or Vj83 CD4 Treg Cells Are Crucial for Spontaneous Recovery from Antigen-induced EAE. Delayed recovery from Acl-9-induced EAE in F1 mice after treatment with Treg-reactive anti-V[3 mAbs indicates that the presence of TCP,-peptide-specific CD4 T cells is crucial for a quick spontaneous recovery in these mice. It is irtteresting that rats tolerized as adults to the VI3 8 CDP,2 peptide contract severe EAE but this tolerance did not result in chronic disease or prolonged recovery (28) Finally, relapses in some of the Treg-depleted animals, as well as the occurrence of chronic EAE in a mouse strain that normally gets an acute episode of EAE, suggest that the spontaneous chronic autoimmune disease course found in some experimental models or in humans could reflect a crucial defect in tight regulation. In monozygotic twins, frequently only one suffers from chronic autoimmune disease: in such cases defective regulation could be decisive in the manifestation of the disease. Conversely, stronger and more efficient regulatory erectors may exist in EAE-resisrant mouse strains, protecting them from antigen-induced autoimmunity. . In (SJL X B10.PL)F1 mice, the initial response to MBP focuses on the immunodominant determinant Acl-9 within the NH2-terminal fragment. However, owing to determinant spreading (24) , T cells reactive to other subdominant determinants, for example, 81-100/A s, and 121-140/A u are revealed in splenic T cell proliferation assays. It has been shown that challenge with certain subdominant peptides in strong adjuvants (CFA and PTx), or adoptive transfer of in vitro-activated T cells into naive mice result in EAE (Kumar, V., unpublished observation; 29). It is not yet clear whether in vivo-primed T cells reactive to these latter determinants are critical for the chronic course of EAE. Our findings in Acl-9~pecific T cell-depleted mice suggest that the continued presence of the initially dominant peptide-reactive T cells may be required for sustaining chronic EAE in this model. However, it is likely that in the chronic-relapsing model of EAE, recruited T cells reactive to newly revealed determinants could participate in the disease, as suggested recently in the SJL mouse (29) .
Chronidty of EAE in Treg-depleted Mice Seems To Be Dependent on the Presence of T Cells Specific for the lmmunodominant Determinant
How Do the CD4 Treg Regulate Responses to MBP? It is likely that activated V[314 + regulatory T cells traffic to inflammatory sites in the central nervous system and locally down-regulate Acl-9-specific responses through secretion of modulatory cytokines, for example, TGF-[3, IL-4, or IL-10 (reviewed in references 4 and 5). Consistent with this notion, the presence of V[314 mP,.NA in central nervous system tissue during recovery from EAE, around day 12, has recently been demonstrated in (PL/J × SJL) mice (30) . Preliminary analysis of the cytokine secretion profile of CD4 Treg reveals that these cells are Th0-1ike in their ability to secrete IL-2 and IFN-% as well as IL-4 and IL-5 (Kumar, V., unpublished observations).
CD8 deletion experiments suggest that once activated, the regulatory B5-reactive CD4 + T cells recruit CD8 + T cells which ultimately down-regulate encephalitogenic T cells (18) . The CD8 cells can recognize distinct TCR determinants in an MHC class I context, displayed on the surface of MBP-specific effector cells (31) . Recognition of the activated, encephalitogenic V[38.2 + effector cells by TCP,-peptide-specific CD8 + T cells may thus be one pathway of specific regulation. Indeed, we have recently characterized a potential class I determinant on the V[38.2 chain distinct from B5. Mice vaccinated with this 10-mer peptide are completely protected from MBP/Acl-9-induced EAE in an unusual dose-related fashion, the protective dose being very low (Kumar, V., unpublished observations). Other experiments in mice devoid of CD8 ÷ T cells, either by anti-CD8 treatment or CD8 gene targeting, have also shown that CD8 cells play an important role in regulating further episodes of EAE (32, 33) .
In conclusion, it is likely that TCP, V[314 + CD4 regulatory T cells are an essential part of a physiological T cell regulatory circuit that establishes tolerance to self MBP in the (SJL X B10.PL)F1 mouse (34) . It appears that disruption of this cellular circuitry can result in an anomalous persistence and chronicity of autoimmune disease.
